Chemed Q4 2025 GAAP EPS down 9%, Roto-Rooter segment weak; guidance for 2026 growth

CHEMED CORP

2025-FY EPS reported $18.34 revenue$2,529,978,000

Revenue $639.3M flat YoY; GAAP diluted EPS $5.48 (-9%), adjusted EPS $6.42 (-6%).
VITAS revenue +1.9% to $418.8M, ADC +1.3% to 22,462, admissions +6%.
Roto-Rooter revenue -3.7% to $220.6M; adjusted EBITDA -21.1%, margin -477bps to 21.5%.
Repurchased 400,000 shares for $174.6M at avg $436.39; $127.3M remaining authorization.
FY2026 adjusted EPS guidance $23.25-$24.25 vs FY2025 $21.55; weighted to H2.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.